Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Acta Biomater. 2019 Mar 28;90:300–313. doi: 10.1016/j.actbio.2019.03.048

Figure 6 |. The evaluation of in vivo antitumor efficiency.

Figure 6 |

(A) Schematic representation of experimental design; (B) In vivo antitumor activity of various formulations in 4T1.2 tumor model. Dox dose was 5mg/kg and IND dose was 20mg/kg. Tumor sizes were plotted as relative tumor volumes; (C) Relative tumor weights at the end point (*P < 0.05; ** P < 0.01; *** P < 0.005, n=5); (D) Representative photomicrographs of tumors with H&E (upper) and Ki-67 immunohistochemical (bottom) staining (Magnification ×200, scale bar = 50 μm).